In each case, connections to PBS-Bio were made through scientific networks involving the Translational Genomics Research Institute (TGen), a Phoenix-based biomedical research facility.
And in each case, PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways the so-called mechanisms of action.
Rather than focusing on a single target or mutation, ENDECE's approach is to identify key molecular switches that prevent tumors from growing out of control.
"We previously identified a primary mechanism of action for how NDC-1308 kills tumor cells. However, the PBS-Bio technology will validate that mechanism and enable us to observe, in real time, the temporal order of changes for components of the pathways that control cancer cell growth," said James Yarger, President and CEO of ENDECE. "In addition, we may obtain data showing the impact, both positive and negative, of NDC-1308 on other cellular pathways. With current technology, we have not been able to identify the temporal order of events."
By working with PBS-Bio, Yarger said, his company also hopes to determine which cancer patients might be the best candidates for the drug and gain an understanding of what current cancer drugs, if any, would be appropriate candidates for combination drug therapies.
"Our bodies fight cancer cells every day, and in general our bodies do it very, very well. However, the appearance of cancerous tumors signifies uncontrolled cancer cell growth and proliferation. When the body's control over some of these pathways are lost, the cancer cells can grow out of control," Yarger said. "ENDECE's focus is on novel therapies that enhance the body's na
|Contact: Dr. Edward Smith|
The Translational Genomics Research Institute